NantKwest Inc. (NASDAQ:NK) Director John C. Thomas sold 6,168 shares of the stock in a transaction on Friday, November 25th. The stock was sold at an average price of $7.50, for a total value of $46,260.00. Following the sale, the director now directly owns 309,621 shares of the company’s stock, valued at $2,322,157.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

NantKwest Inc. (NASDAQ:NK) opened at 6.54 on Thursday. NantKwest Inc. has a 1-year low of $5.43 and a 1-year high of $18.74. The stock’s 50 day moving average price is $6.84 and its 200 day moving average price is $7.14. The firm’s market cap is $538.73 million.

TRADEMARK VIOLATION WARNING: This story was first posted by Financial Market News and is the propert of of Financial Market News. If you are accessing this story on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be viewed at http://www.financial-market-news.com/john-c-thomas-sells-6168-shares-of-nantkwest-inc-nk-stock/1212302/.

Large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. increased its stake in shares of NantKwest by 2.2% in the first quarter. JPMorgan Chase & Co. now owns 152,196 shares of the company’s stock worth $1,251,000 after buying an additional 3,309 shares during the period. Bank of New York Mellon Corp increased its stake in shares of NantKwest by 39.4% in the second quarter. Bank of New York Mellon Corp now owns 78,443 shares of the company’s stock worth $487,000 after buying an additional 22,155 shares during the period. California State Teachers Retirement System increased its stake in shares of NantKwest by 144.2% in the second quarter. California State Teachers Retirement System now owns 34,954 shares of the company’s stock worth $217,000 after buying an additional 20,643 shares during the period. Swiss National Bank increased its stake in shares of NantKwest by 16.8% in the second quarter. Swiss National Bank now owns 42,450 shares of the company’s stock worth $264,000 after buying an additional 6,100 shares during the period. Finally, Emerald Acquisition Ltd. purchased a new stake in shares of NantKwest during the second quarter worth $228,000. Institutional investors and hedge funds own 24.23% of the company’s stock.

Several equities research analysts recently weighed in on NK shares. Canaccord Genuity reaffirmed a “buy” rating and set a $18.00 price target on shares of NantKwest in a report on Friday, August 19th. Zacks Investment Research raised NantKwest from a “hold” rating to a “buy” rating and set a $8.50 target price for the company in a report on Saturday, November 19th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and issued a $23.00 target price (down previously from $32.00) on shares of NantKwest in a report on Wednesday, August 17th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $17.70.

About NantKwest

NantKwest, Inc, formerly Conkwest, Inc, is a biotechnology company engaged in developing targeted direct-acting immunotherapeutic agents for a range of clinical conditions. The Company is focused on harnessing its immune system by using the natural killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases.

5 Day Chart for NASDAQ:NK

Receive News & Ratings for NantKwest Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantKwest Inc. and related companies with MarketBeat.com's FREE daily email newsletter.